Global Biosimilar Expansion Lek, a Sandoz company, is a leading biosimilar developer with ongoing large-scale investments, including a new US$440 million biosimilar production facility in Slovenia. This indicates substantial capacity and global supply readiness, suggesting opportunities to position compatible biosimilar products and services to evolving markets.

Strong Slovenian Footprint As the largest biosimilars provider and a top generics player in Slovenia, Lek has deep market access, regulatory familiarity, and governmental relationships. This creates a favorable entry point for regional partnerships, contract manufacturing, and supply agreements across Southeast Europe.

R&D Investment Engine With over €100 million annually invested in development and 80 years of heritage, Lek demonstrates sustained focus on R&D and product development. This presents opportunities for co-development, technology licensing, and early access programs for healthcare systems seeking affordable innovative therapies.

Scale and Talent Employing over 4,000 associates and expanding headcount through recent and planned investments, Lek offers a robust workforce for scale-up collaborations, clinical operations support, and manufacturing partnerships, including potential for regional capability building and knowledge transfer services.

Global Market Reach Lek supplies nearly 60 markets and is integrated within Sandoz's global network, presenting multiregional procurement opportunities, strategic alliances, and distribution collaborations for high-quality generics, biosimilars, and API manufacturing across diverse healthcare systems.